# MoonRISe-3: HCP commentary report

> 122 verified statements (76 from speakers with a confirmed clinical role) from 9 commentary sources · 7 findings · updated Oct 19, 2026

## Report

- Trial: A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
- NCT ID: NCT06919965
- Registry: https://clinicaltrials.gov/study/NCT06919965
- Sponsor: Janssen Research & Development, LLC
- Phase: Phase 3
- Status: Recruiting
- Drugs: gemcitabine
- Version: v1.0.0, edition 1
- Accepted: 2026-10-19
- Last checked: 2026-10-19
- Release hash: c536c61917df22bdf6fb3347a134fef73e733231741258adb676cb74f8da4445

## Counts

- HCP commentary sources screened: 10
- Sources cited by verified statements: 9
- Verified statements: 122
- From speakers with a confirmed clinical role: 76
- Findings: 7
- People found in screened sources: 9
- People identity-verified: 6
- Voices cited: 9

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

MoonRISe-3 asks whether bladder-delivered TAR-210 improves disease-free survival over intravesical chemotherapy in FGFR-altered, high-risk papillary non-muscle-invasive bladder cancer after BCG. Clinicians in the sources reviewed for this edition express optimism about TAR-210's potential, while expectations remain conditional. Earlier-phase activity and randomization are welcomed, while patient selection draws scrutiny. Comparative benefit remains unresolved, alongside questions about how to identify appropriate patients for TAR-210 and interpret their risk after BCG.

## Open Medical Affairs question

What evidence would distinguish biomarker-associated activity from greater benefit specifically attributable to selecting TAR-210 over non-targeted intravesical alternatives?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. A strong preference for TAR-210 did not resolve its comparative value in FGFR-altered disease
- F2. Bladder preservation remained conditional on surgical counseling, disease risk and prior-treatment uncertainty
- F3. Local-treatment preferences did not establish a ranking or eliminate a systemic role
- F4. Earlier-phase activity generated optimism, with explicit warnings against treating it as Phase 3 confirmation
- F5. Randomization was valued as a response to the papillary-only evidence and approval gap
- F6. Risk, BCG-response categories and molecular eligibility were separate sources of selection uncertainty
- F7. Access and multidisciplinary support could matter as much as the availability of another option

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 14 | 6 | 2 | 3 | recorded | 2 |
| F2 | 18 | 9 | 2 | 4 | recorded | 4 |
| F3 | 17 | 14 | 3 | 4 | recorded | 6 |
| F4 | 11 | 7 | 5 | 3 | none recorded | 3 |
| F5 | 9 | 7 | 6 | 5 | none recorded | 3 |
| F6 | 15 | 8 | 4 | 3 | recorded | 3 |
| F7 | 11 | 7 | 4 | 3 | recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 3 | 6 | 0 | 1 | 4 | 14 | 0 | 2 podcasts and video | yes |
| F2 | 5 | 4 | 3 | 1 | 5 | 18 | 7 | 2 podcasts and video | yes |
| F3 | 6 | 3 | 0 | 3 | 5 | 20 | 3 | 3 podcasts and video | yes |
| F4 | 3 | 4 | 0 | 0 | 4 | 11 | 1 | 2 posts and articles, 3 podcasts and video | yes |
| F5 | 1 | 1 | 0 | 2 | 5 | 9 | 0 | 3 posts and articles, 3 podcasts and video | yes |
| F6 | 6 | 0 | 0 | 2 | 7 | 15 | 0 | 1 post or article, 3 podcasts and video | yes |
| F7 | 3 | 2 | 1 | 1 | 4 | 12 | 2 | 4 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: Disease-free Survival (DFS): F4 (1 shared claims), F5 (2 shared claims), F6 (1 shared claims)
- Secondary endpoints: no finding draws on it directly
- Population and setting: F5 (3 shared claims), F6 (15 shared claims), F7 (1 shared claims)
- The comparison: F4 (1 shared claims), F5 (3 shared claims), F6 (1 shared claims)
- Safety and tolerability: F1 (3 shared claims)
- Design and conduct: F5 (4 shared claims), F6 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F5. Randomization was valued as a response to the papillary-only evidence and approval gap

A podcast interview explores what kind of clinical evidence could support treatment approvals for papillary-only bladder cancer after BCG.

Approval and recruitment descriptions reflect the interview period and should not be read as current status.

Source: podcast, 2025-11-15.

### F6. Risk, BCG-response categories and molecular eligibility were separate sources of selection uncertainty

A podcast interviewer asks how risk groups and BCG-response categories are defined for non-muscle-invasive bladder cancer.

The full trial protocol was not available in the sources reviewed for this edition; the discussion does not establish an individual patient's trial eligibility.

Source: podcast, 2025-11-15.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 122 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 9 | Counts free |
| Speaker attribution for cited voices | 9 | Paid |

## Trial aspects

10 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Disease-free Survival (DFS) | discussed | 2 | 2 |
| Secondary endpoints | no commentary found | 0 | 0 |
| Population and setting | discussed | 16 | 5 |
| The comparison | discussed | 3 | 3 |
| Safety and tolerability | discussed | 7 | 3 |
| Design and conduct | discussed | 4 | 3 |
| Earlier-phase promise and conditional future impact | discussed | 11 | 5 |
| Does FGFR selection favor TAR-210 over other local options? | discussed | 12 | 2 |
| Cystectomy counseling and uncertainty after multiple prior treatments | discussed | 18 | 2 |
| Local versus systemic treatment, tentative alternative rankings and selective immune-therapy exceptions | discussed | 17 | 3 |
| Papillary-only approval needs, access and multidisciplinary support | discussed | 12 | 5 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 4 | 3 |
| Podcasts | 3 | 3 |
| YouTube | 2 | 2 |
| Bluesky threads | 1 | 1 |

- Screened window: 2025-04-28 to 2026-05-17
- Cited window: 2025-04-28 to 2026-05-17
- Retrieved: 2026-10-19

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
- Registry: NCT06919965 (https://clinicaltrials.gov/study/NCT06919965)
- Study IDs: 42756493BLC3005 · 2024-519493-39-00 (EUCT number)
- Sponsor: Janssen Research & Development, LLC
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 220 (estimated)
- Start: 2025-09-10 (actual)
- Primary completion: 2028-04-06 (estimated)
- Primary endpoint: Disease-free Survival (DFS) (Up to 5 years)
- Intervention: TAR-210 (drug)
- Intervention: Mitomycin C (drug)
- Intervention: Gemcitabine (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- Out of scope: 3 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
- 188 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed provide qualitative views, not a representative estimate of HCP agreement, treatment use or patient outcomes.
- Podcast and video coverage overlaps for the March 2026-published educational session; source totals must not be interpreted as independent clinician totals.
- Discussions using unnamed references or different wording may be absent. Two relevant passages were not fully assessed; additional views and qualifications concerning treatment alternatives, toxicity, patient selection and evidence limitations may be missing.
- No full protocol or results publication for NCT06919965 was available among the reviewed materials. The report cannot independently assess all eligibility details, endpoint definitions or comparative results.
- Earlier TAR-210 recurrence estimates came from separate source accounts and were explicitly preliminary; their numerical differences cannot be reconciled from these statements.
- Some connected post-BCG counseling discussions did not state FGFR status. Other alternative-treatment opinions expressly concerned BCG-refractory CIS. These discussions inform the treatment decision but do not demonstrate eligibility for, or efficacy in, MoonRISe-3.
- Joanna Sadowska Aka Dr Jojo's individual identity is unverified and the sources reviewed do not establish a clinical role. Félix Guerrero-Ramos's individual identity is also unverified.
- Exact TAR-210 and mitomycin C labels were not available among the reviewed materials. Speakers' approval, availability and geographic-access remarks are not a current labeling or reimbursement assessment. The case presenter's TAR-200 availability statement was relative to the presentation, not evidence of current access in every country.
- Source publication dates do not establish the date of every session, readout or recruitment milestone, and do not by themselves demonstrate a change of mind.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-19: current edition

Last checked for new commentary 2026-10-19. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (122 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (6 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/moonrise-3-nct06919965
- Agents: POST https://www.erudio.com/api/orders with {"report": "moonrise-3-nct06919965", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=moonrise-3-06919965

## Cite

Erudio Health. MoonRISe-3 (NCT06919965): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 19, 2026. https://www.erudio.com/reports/moonrise-3-nct06919965

## Machine access

- JSON: https://www.erudio.com/reports/moonrise-3-nct06919965.json
- Markdown: https://www.erudio.com/reports/moonrise-3-nct06919965.md
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "moonrise-3-06919965"}`